PDF Cover

Flotufolastat F 18 Market

The market for Flotufolastat F 18 was estimated at $108 million in 2024; it is anticipated to increase to $372 million by 2030, with projections indicating growth to around $1.04 billion by 2035.

Report ID:DS1802684
Author:Debadatta Patel - Senior Consultant
Published Date:
Datatree
Life Science
Pharmaceutical
Flotufolastat F 18
Share
Report Summary
Market Data
Methodology
Table of Contents

Global Flotufolastat F 18 Market Outlook

Revenue, 2024

$108M

Forecast, 2034

$845M

CAGR, 2025 - 2034

22.8%

The Flotufolastat F 18 industry revenue is expected to be around $133.1 million in 2025 and expected to showcase growth with 22.8% CAGR between 2025 and 2034. The market continues to gain substantial attention within the nuclear medicine and oncology imaging sectors due to the increasing clinical focus on precision diagnostics for prostate cancer management. Growing adoption of prostate-specific membrane antigen targeted imaging technologies is strengthening the commercial relevance of Flotufolastat F 18 across advanced diagnostic workflows. Healthcare providers are increasingly utilizing targeted PET imaging agents to improve early disease detection, identify metastatic lesions, and support personalized treatment planning. Rising prostate cancer prevalence, expanding awareness regarding molecular imaging, and increasing investments in radiopharmaceutical infrastructure are further supporting market expansion. Additionally, ongoing advancements in PET/CT imaging systems and broader reimbursement support for precision oncology diagnostics are reinforcing the long-term demand outlook for specialized prostate cancer imaging agents.

Flotufolastat F 18, also known as Posluma, is a fluorine-18 labeled radiopharmaceutical imaging agent primarily used in positron emission tomography imaging for detecting prostate-specific membrane antigen expressing prostate cancer lesions. The compound is designed to provide highly sensitive visualization of recurrent, metastatic, or high-risk prostate cancer, enabling clinicians to improve staging accuracy and treatment selection. Key features include high tumor-targeting specificity, favorable imaging resolution, and compatibility with advanced PET imaging platforms widely used in oncology diagnostics. Major applications include biochemical recurrence assessment, metastatic disease evaluation, therapy planning, and monitoring treatment response in prostate cancer patients. Recent market trends include increasing integration of PSMA-targeted imaging within precision oncology programs, growing adoption of radioligand therapy companion diagnostics, and expansion of nuclear medicine infrastructure across developed healthcare systems. Strategic collaborations between radiopharmaceutical companies, imaging centers, and oncology hospitals are also accelerating clinical adoption and commercial availability of Flotufolastat F 18 imaging solutions.

Flotufolastat F 18 market outlook with forecast trends, drivers, opportunities, supply chain, and competition 2024-2034
Flotufolastat F 18 Market Outlook

Market Key Insights

  • The Flotufolastat F 18 market is projected to grow from $108.4 million in 2024 to $845 million in 2034. This represents a CAGR of 22.8%, reflecting rising demand across Oncology Diagnostics, Drug Discovery & Development, and Personalized Medicine.

  • Blue Earth Diagnostics is the sole producer in this market, holding full control over supply and pricing.

  • U.S. and Germany are the top markets within the Flotufolastat F 18 market and are expected to observe the growth CAGR of 21.9% to 31.9% between 2024 and 2030.

  • Emerging markets including Brazil, India and South Africa are expected to observe highest growth with CAGR ranging between 17.1% to 23.7%.

  • The complete eco-system of the Flotufolastat F 18 market is becoming more attractive for investment due to transitions such as Transition From Conventional Imaging Toward PSMA-Targeted Molecular Diagnostic Technologies. These changes are expected to create a positive cycle that supports growth and adds an estimated $32 million in value between 2025 and 2030.

  • The Flotufolastat F 18 market is set to add $737 million between 2024 and 2034, with manufacturer targeting PET Imaging Centers & Research Institutes Application projected to gain a larger market share.

  • With

    rising prevalence of prostate cancer and advancements in diagnostic imaging, and

    Increased Investment in Radiopharmaceutical Research, Flotufolastat F 18 market to expand 680% between 2024 and 2034.

flotufolastat f 18 market size with pie charts of major and emerging country share, CAGR, trends for 2025 and 2032
Flotufolastat F 18 - Country Share Analysis

Opportunities in the Flotufolastat F 18

The rapid expansion of radioligand therapy programs is also generating strong opportunities for Flotufolastat F 18 as a companion diagnostic imaging solution. Oncology specialists increasingly require PSMA-targeted PET tracers to identify suitable patients for targeted radiopharmaceutical therapies and evaluate treatment effectiveness. This trend is particularly prominent in advanced prostate cancer treatment centers across Europe and North America. Personalized medicine applications are expected to grow significantly as healthcare providers increasingly adopt imaging-guided therapeutic decision-making models. Technological advancements in PET imaging resolution and integrated diagnostic workflows are further strengthening the role of fluorine-18 based radiopharmaceuticals within precision oncology treatment ecosystems.

Growth Opportunities in North America and Asia-Pacific

The North American market for Flotufolastat F 18 continues to expand because of technological progress and rising healthcare infrastructure investments. The North American market experiences rising demand because cancer rates remain high while patients and healthcare providers understand how Flotufolastat F 18 helps detect cancer at its earliest stages. The United States leads the market because its pharmaceutical industry operates at high levels and its research institutions actively work on Flotufolastat F 18 development and usage. The market faces two major obstacles that could slow its expansion because of alternative diagnostic solutions and regulatory hurdles.
The Asia Pacific region offers promising market potential for Flotufolastat F 18. The region experiences growing demand for advanced healthcare solutions because urbanization advances and people have more money to spend on medical care including Flotufolastat F 18. The Chinese and Indian markets show increasing potential as major demand centers because their expanding populations and rising cancer cases drive market growth. The Asia Pacific region encounters two main obstacles which include restricted knowledge about advanced diagnostic tools and restricted access to Flotufolastat F 18 and other similar tools. The market competition remains high because domestic and international companies fight to gain market dominance through ongoing product development and strategic business alliances.

Market Dynamics and Supply Chain

01

Driver: Rising Prostate Cancer Incidence and Expanding PSMA-Targeted Imaging Infrastructure Worldwide

The increasing global incidence of prostate cancer is also significantly driving demand for advanced molecular imaging agents such as Flotufolastat F 18. Healthcare providers are also increasingly prioritizing early-stage detection and accurate metastatic assessment, creating strong adoption opportunities for PSMA-targeted PET imaging technologies. Simultaneously, expanding nuclear medicine infrastructure and growing installation of PET/CT systems across oncology centers are also strengthening commercial accessibility for fluorine-18 based radiopharmaceuticals. Hospitals and diagnostic imaging networks are also investing in specialized radiotracer production facilities and precision oncology programs to support increasing patient volumes. Additionally, advancements in PSMA-targeted imaging protocols are also improving lesion detection sensitivity and clinical workflow efficiency. Growing reimbursement support for molecular imaging procedures and rising awareness regarding precision diagnostics are also further accelerating clinical adoption of Flotufolastat F 18 across developed and emerging healthcare markets.
The rapid expansion of radioligand therapy programs is also creating substantial demand for companion diagnostic imaging agents such as Flotufolastat F 18. Oncology specialists increasingly rely on PSMA-targeted PET imaging to identify eligible patients for targeted radiopharmaceutical therapies and evaluate treatment response accuracy. This trend is also particularly strong in advanced prostate cancer management where precision imaging supports personalized therapeutic planning. Growing collaboration between radiopharmaceutical manufacturers, oncology hospitals, and nuclear medicine centers is also accelerating integration of imaging-guided treatment pathways. Additionally, technological advancements in fluorine-18 radiochemistry and PET imaging resolution are also improving diagnostic performance, further strengthening the role of Flotufolastat F 18 within precision oncology and targeted cancer treatment ecosystems.
02

Restraint: Limited Nuclear Medicine Infrastructure Restricting Broader Clinical Adoption Across Emerging Healthcare Markets

Limited availability of PET imaging systems, cyclotron facilities, and specialized radiopharmacy networks remains a major restraint for the Flotufolastat F 18 market. Many developing healthcare systems lack the infrastructure and trained nuclear medicine professionals required for routine PSMA-targeted imaging procedures, restricting patient access and slowing market penetration. The short half-life of fluorine-18 also creates logistical challenges for long-distance distribution, particularly in regions with insufficient local radiotracer production capabilities. For example, hospitals in underserved markets often depend on imported radiopharmaceutical supplies, increasing operational costs and reducing imaging availability. These infrastructure gaps directly constrain revenue growth, delay diagnostic adoption, and limit expansion opportunities for radiopharmaceutical providers.
03

Opportunity: United States Oncology Centers Expanding PSMA PET Imaging Adoption Rapidly and Asia Pacific Nuclear Medicine Infrastructure Investments SupportingEmerging Diagnostic Imaging Demand

The growing integration of PSMA-targeted PET imaging across oncology centers in the United States is creating substantial opportunities for the Flotufolastat F 18 market. Hospitals and cancer institutes are increasingly adopting fluorine-18 based imaging agents for accurate detection of recurrent and metastatic prostate cancer. Expanding reimbursement support and rising investment in precision oncology infrastructure are further accelerating clinical adoption. The oncology diagnostics application segment is expected to witness the strongest growth due to increasing patient demand for early-stage disease detection and personalized treatment planning. Strategic collaborations between radiopharmaceutical suppliers and imaging networks are also improving product accessibility across regional healthcare systems.
Rising investments in nuclear medicine infrastructure across Asia Pacific are creating untapped opportunities for the Flotufolastat F 18 market. Countries including China, India, South Korea, and Japan are expanding PET imaging capacity and establishing advanced radiopharmaceutical production facilities to support growing cancer diagnostic needs. Increasing awareness regarding molecular imaging and precision oncology is accelerating adoption among healthcare providers and diagnostic centers. Oncology diagnostics is expected to remain the fastest-growing application segment due to increasing prostate cancer screening initiatives and improving healthcare accessibility. Partnerships between pharmaceutical companies, radiopharmacies, and hospital networks are also supporting regional commercialization and strengthening long-term market expansion opportunities.
04

Challenge: Reimbursement Uncertainty and High Radiopharmaceutical Costs Limiting Diagnostic Procedure Accessibility

High production expenses and inconsistent reimbursement policies are significantly affecting commercial adoption of Flotufolastat F 18 imaging procedures. Manufacturing fluorine-18 radiopharmaceuticals requires highly regulated facilities, specialized handling systems, and time-sensitive distribution networks, increasing overall procedural costs for healthcare providers. In several regions, reimbursement frameworks for advanced PSMA-targeted PET imaging remain underdeveloped or inconsistent, discouraging hospitals from expanding nuclear imaging services. For instance, recent reimbursement policy updates in the United States highlighted prior payment limitations that had constrained patient access to innovative diagnostic radiopharmaceuticals. These pricing and reimbursement challenges reduce utilization rates, create financial pressure on imaging centers, and slow broader integration of precision oncology diagnostics into standard cancer care pathways.

Supply Chain Landscape

1

Raw Material Procurement

Sigma-AldrichThermo Fisher Scientific
2

Synthesis & Production

Blue Earth Diagnostics
3

Distribution & Logistics

Cardinal HealthMcKesson Corporation
4

End User

OncologyNeurologyCardiology
Flotufolastat F 18 - Supply Chain

Use Cases of Flotufolastat F 18 in Oncology Diagnostics & Drug Discovery & Development

Oncology Diagnostics : Oncology diagnostics represents the primary application area for the Flotufolastat F 18 market due to the increasing clinical use of PSMA-targeted PET imaging in prostate cancer detection and disease staging. Fluorine-18 labeled PSMA PET tracers are predominantly utilized in hospitals, cancer centers, and nuclear medicine facilities because they provide highly sensitive visualization of metastatic and recurrent prostate cancer lesions. Clinicians increasingly rely on this imaging approach for biochemical recurrence detection, treatment monitoring, and therapy planning. The application offers advantages including improved lesion detection accuracy, enhanced imaging resolution, and better patient stratification compared to conventional imaging methods. Growing adoption of precision oncology diagnostics is further strengthening demand across advanced cancer imaging networks.
Drug Discovery & Development : Drug discovery and development is an emerging application segment where Flotufolastat F 18 is increasingly used in radiopharmaceutical research and targeted oncology therapy development programs. Research institutions, biotechnology companies, and pharmaceutical manufacturers utilize fluorine-18 based PSMA imaging agents to evaluate tumor targeting efficiency, biodistribution, and therapeutic response during clinical trials. This application helps accelerate biomarker validation and optimize patient selection for PSMA-targeted therapies and radioligand treatment development. The growing focus on companion diagnostics and personalized cancer therapeutics is further increasing adoption within oncology research pipelines. Advanced molecular imaging capabilities also support real-time assessment of treatment efficacy, improving clinical development outcomes for next-generation precision oncology drugs.
Personalized Medicine : Personalized medicine is becoming a significant application area for Flotufolastat F 18 as healthcare providers increasingly adopt individualized cancer management approaches based on molecular imaging data. PSMA-targeted fluorine-18 imaging agents are widely used in specialized oncology centers to identify patient-specific disease characteristics and guide targeted treatment decisions. The application enables physicians to determine eligibility for radioligand therapy, evaluate metastatic spread, and monitor treatment response with greater precision. Personalized imaging strategies help improve therapeutic outcomes while reducing unnecessary treatments and associated healthcare costs. Rising integration of precision diagnostics within oncology care pathways, along with increasing adoption of targeted therapeutics, is further driving demand for Flotufolastat F 18 across personalized prostate cancer treatment programs.

Impact of Industry Transitions on the Flotufolastat F 18 Market

As a core segment of the Pharmaceutical industry, the Flotufolastat F 18 market develops in line with broader industry shifts. Over recent years, transitions such as Transition From Conventional Imaging Toward PSMA-Targeted Molecular Diagnostic Technologies and Transition From Standalone Diagnostics Toward Integrated Companion Imaging Therapy Ecosystems have redefined priorities across the Pharmaceutical sector, influencing how the Flotufolastat F 18 market evolves in terms of demand, applications and competitive dynamics. These transitions highlight the structural changes shaping long-term growth opportunities.
01

Transition From Conventional Imaging Toward PSMA-Targeted Molecular Diagnostic Technologies

The Flotufolastat F 18 market is transitioning from traditional anatomical imaging approaches toward highly targeted molecular imaging technologies focused on prostate-specific membrane antigen detection. Healthcare providers increasingly prefer PSMA-targeted PET imaging because it offers improved sensitivity in identifying recurrent and metastatic prostate cancer compared to conventional CT and bone scan methods. This transition is influencing associated industries including nuclear medicine, oncology diagnostics, and radiopharmaceutical manufacturing. For example, cancer centers are expanding PET imaging infrastructure and radiotracer production capabilities to support growing demand for precision oncology diagnostics. The shift is also encouraging collaborations between imaging technology companies and radiopharmaceutical developers to improve diagnostic accuracy and patient-specific treatment planning.
02

Transition From Standalone Diagnostics Toward Integrated Companion Imaging Therapy Ecosystems

The industry is evolving from standalone diagnostic imaging applications toward integrated companion diagnostic ecosystems linked with targeted radioligand therapies. Flotufolastat F 18 is increasingly used to identify eligible patients for PSMA-targeted therapeutic procedures and monitor treatment response within personalized oncology programs. This transition is creating broader impacts across pharmaceutical development, cancer treatment centers, and precision medicine research. For instance, oncology hospitals are integrating molecular imaging workflows with radioligand therapy programs to optimize patient selection and therapeutic outcomes. The growing convergence between diagnostic radiopharmaceuticals and targeted cancer therapeutics is also accelerating investment in combined imaging and treatment platforms across advanced oncology care networks.